<DOC>
	<DOC>NCT02264054</DOC>
	<brief_summary>Study to investigate metabolism, pharmacokinetic, safety and tolerability of talsaclidine.</brief_summary>
	<brief_title>Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males Age range from 50 to 65 years Participants should be within 20% of their normal weight (BrocaIndex) Written informed consent in accordance with Good Clinical Practice and local legislation Results of the medical examination or laboratory tests (especially those which indicate liver malfunction) are judged by the clinical investigator to differ significantly from normal clinical values Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Disease of the central nervous system (such as epilepsy) or with psychiatric disorders Known history of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (≥ 24 hours) within one month before enrolment in the study Intake of any other drugs which might influence the results of the trial during the week previous the start of the study Participation in another study with an investigational drug within the last 2 months preceding this study Unability to refrain from smoking on study days Volunteers who smoke more than 10 cigarettes (or 3 cigars or pipes) per day Volunteers who drink more than 40 g of alcohol per day Volunteers who are dependent on drugs Blood donation ((≥ 100 ml) within the last 4 weeks Excessive physical activities (e.g. competitive sports) within the last week before the study</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>